Top-News

Sio Gene Therapies Inc. News

Keine aktuellen Kursdaten verfügbar
WKN: A2QHKW
ISIN: US8293991043
US-Symbol: SIOX
Typ: Aktie

Sio Gene Therapies Inc. News

04.01.22 - PR Newswire
Thinking about buying stock in Plus Therapeutics, Neurobo Pharmaceuticals, Flora Growth, Paysign, or Sio Gene Therapies?
Thinking about buying stock in Plus Therapeutics, Neurobo Pharmaceuticals, Flora Growth, Paysign, or Sio Gene Therapies? PR Newswire
21.10.21 - PR Newswire
Thinking about buying stock in Nextplay Technologies, Sio Gene Therapies, Kadmon, Senseonics, or InMed Pharmaceuticals?
Thinking about buying stock in Nextplay Technologies, Sio Gene Therapies, Kadmon, Senseonics, or InMed Pharmaceuticals? PR Newswire
04.10.21 - PR Newswire
Thinking about buying stock in OpGen, Adverum Biotechnologies, OraSure Technologies, Sonnet BioTherapeutics, or Sio Gene Therapies?
Thinking about buying stock in OpGen, Adverum Biotechnologies, OraSure Technologies, Sonnet BioTherapeutics, or Sio Gene Therapies? PR Newswire
25.06.21 - PR Newswire
Thinking about buying stock in Osmotica Pharmaceuticals, Property Solutions Acquisition, Sio Gene Therapies, Clearside Biomedical, or Sorrento Therapeutics?
Thinking about buying stock in Osmotica Pharmaceuticals, Property Solutions Acquisition, Sio Gene Therapies, Clearside Biomedical, or Sorrento Therapeutics? PR Newswire
15.06.21 - PR Newswire
Thinking about buying stock in Eloxx Pharmaceuticals, Sio Gene Therapies, Ampio Pharmaceuticals, Applied Genetic Technologies, or Cyclo Therapeutics?
Thinking about buying stock in Eloxx Pharmaceuticals, Sio Gene Therapies, Ampio Pharmaceuticals, Applied Genetic Technologies, or Cyclo Therapeutics? PR Newswire
10.11.20 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axovant Gene Therapies Ltd. - AXGT
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axovant Gene Therapies Ltd. - AXGT PR Newswire
23.09.20 - PR Newswire
Thinking about buying stock in Axovant Gene Therapies, MediciNova, Canada Goose Holdings, Rite Aid Corp, or Wave Life Sciences?
Thinking about buying stock in Axovant Gene Therapies, MediciNova, Canada Goose Holdings, Rite Aid Corp, or Wave Life Sciences? PR Newswire
21.09.20 - PR Newswire
Thinking about buying stock in Wave Life Sciences, Axovant Gene Therapies, Lipocine Inc, Workhorse Group, or Cassava Sciences?
Thinking about buying stock in Wave Life Sciences, Axovant Gene Therapies, Lipocine Inc, Workhorse Group, or Cassava Sciences? PR Newswire
17.05.19 - PR Newswire
NIH administers first clinical trial treatment for GM1 created by Auburn, UMass
NIH administers first clinical trial treatment for GM1 created by Auburn, UMass Milestone marks the first patient with GM1 gangliosidosis treated with gene therapy PR Newswire
02.01.19 - PR Newswire
Roivant Sciences to Present at the 37th Annual J.P. Morgan Healthcare Conference
Roivant Sciences to Present at the 37th Annual J.P. Morgan Healthcare Conference - In addition to Roivant, four Vants will be presenting at JPM this year PR Newswire
19.12.18 - PR Newswire
Roivant Sciences and Daiichi Sankyo Enter into Broad Pipeline Partnership
Roivant Sciences and Daiichi Sankyo Enter into Broad Pipeline Partnership PR Newswire
26.11.18 - PR Newswire
Roivant Launches Aruvant Sciences and Roivant Foundation in Partnership with Cincinnati Children's Hospital Medical Center
Roivant Launches Aruvant Sciences and Roivant Foundation in Partnership with Cincinnati Children's Hospital Medical Center - Aruvant's pipeline anchored by RVT-1801, an ...
17.09.18 - PR Newswire
Roivant Launches Respivant Sciences to Develop Innovative Therapeutics for Respiratory Diseases
Roivant Launches Respivant Sciences to Develop Innovative Therapeutics for Respiratory Diseases - Respivant to be led by Bill Gerhart, former CEO of Patara Pharma and ...
07.06.18 - PR Newswire
Thinking about buying stock in Axovant Sciences, Cronos Group, Micron, Netflix or AT&T?
Thinking about buying stock in Axovant Sciences, Cronos Group, Micron, Netflix or AT&T? PR Newswire
26.09.17 - Börse Online
Rekordverdächtig: Axovant-Aktie minus 70 Prozent - Alzheimer-Mittel floppt
Ein Rückschlag für ein Alzheimer-​Medikament hat Axovant am Dienstag den größten Kurssturz der Firmengeschichte eingebrockt. Die Aktie der Pharmafirma fiel im vorbörslichen ...
26.09.17 - PR Newswire
Axovant Announces Negative Topline Results of Intepirdine Phase 3 MINDSET Trial in Alzheimer's Disease
Axovant Announces Negative Topline Results of Intepirdine Phase 3 MINDSET Trial in Alzheimer's Disease --Conference call today at 8:00 a.m. EDT-- PR Newswire
06.09.17 - PR Newswire
Axovant to Present at Two Upcoming Investor Conferences
Axovant to Present at Two Upcoming Investor Conferences PR Newswire
21.08.17 - PR Newswire
Axovant to Move Stock Exchange Listing to Nasdaq
Axovant to Move Stock Exchange Listing to Nasdaq -- Ticker Symbol to Remain AXON -- PR Newswire
07.08.17 - PR Newswire
Axovant Announces Fiscal First Quarter Financial Results and Corporate Updates
Axovant Announces Fiscal First Quarter Financial Results and Corporate Updates PR Newswire
19.07.17 - PR Newswire
New Preclinical Data for Intepirdine Suggests Potential Neuroprotective Properties
New Preclinical Data for Intepirdine Suggests Potential Neuroprotective Properties PR Newswire

Newssuche

Videos

newspaper
08:40 Uhr +6,31%
Technical Trading: Gold Long freitags
Gold Long Typ: Turbo Open End WKN: NG8DB8 Hebel: 27 Laufzeit: OpenEnd Einstieg: Market ... Mehr »